![conference banner](/images/conference-banner.jpeg)
Abstract
Background: LncRNA is a kind of non-coding RNA and its research is more popular in recent years, which has more than 200 nucleotides. It plays a significant part in various biological functions, including chromosome modification, genome modification, transcriptional activation, transcriptional interference, and other processes. FTX, at the center of the X chromosome inactivation and it has been shown that lncRNA FTX regulates cancer cells’ development, migration, and invasion in many studies.
Methods: Relevant literature was collected through the PubMed system search and is summarized in this article.
Results: LncRNA FTX abnormally increased in tumor cells, such as liver cancer, stomach cancer, leukemia, renal cell carcinoma, colorectal cancer, glioma, osteosarcoma, etc. However, the expression level decreased in temporal lobe epilepsy, liver cirrhosis, heart failure, etc.
Conclusion: FTX may be an important regulatory factor and a potential therapeutic target in cancers.
Keywords: LncRNA FTX, cancer, temporal lobe epilepsy, cirrhosis, heart failure, osteosarcoma.
[http://dx.doi.org/10.1093/hmg/ddq516] [PMID: 21118898]
[http://dx.doi.org/10.3892/ijo.2018.4418] [PMID: 29845188]
[http://dx.doi.org/10.1080/15384047.2019.1702405] [PMID: 31920141]
[PMID: 31949847]
[http://dx.doi.org/10.1016/j.urolonc.2014.10.014]
[http://dx.doi.org/10.3727/096504016X14719078133203] [PMID: 27983937]
[http://dx.doi.org/10.3322/caac.21220] [PMID: 24639052]
[http://dx.doi.org/10.1038/s41434-018-0026-7] [PMID: 29925853]
[PMID: 26629053]
[http://dx.doi.org/10.7150/thno.20942] [PMID: 29187907]
[PMID: 28337275]
[http://dx.doi.org/10.1038/s41389-017-0006-6] [PMID: 29199273]
[http://dx.doi.org/10.1038/ncpneuro0289]
[http://dx.doi.org/10.1007/s00401-007-0243-4] [PMID: 17618441]
[http://dx.doi.org/10.1038/labinvest.2016.152] [PMID: 28112756]
[http://dx.doi.org/10.1002/prca.201900053] [PMID: 31709769]
[http://dx.doi.org/10.1056/NEJMra1406184] [PMID: 26376137]
[http://dx.doi.org/10.1038/s41419-018-0706-7] [PMID: 29880818]
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[http://dx.doi.org/10.1038/onc.2016.80] [PMID: 27065331]
[http://dx.doi.org/10.18632/oncotarget.8129] [PMID: 26992218]
[http://dx.doi.org/10.1371/journal.pone.0109782] [PMID: 25299640]
[http://dx.doi.org/10.1016/j.bbrc.2019.03.019] [PMID: 30871773]
[PMID: 30304545]
[http://dx.doi.org/10.12659/MSM.919654] [PMID: 31840653]
[http://dx.doi.org/10.3389/fphar.2018.00896] [PMID: 30150938]
[http://dx.doi.org/10.1016/j.gene.2019.143995] [PMID: 31336140]
[http://dx.doi.org/10.1016/S0092-8674(02)00969-8] [PMID: 12297047]
[http://dx.doi.org/10.1007/s10741-016-9532-0] [PMID: 26872675]
[http://dx.doi.org/10.1038/nrd.2016.253] [PMID: 28209992]
[http://dx.doi.org/10.1038/nrm3722] [PMID: 24355989]
[http://dx.doi.org/10.1016/j.bbrc.2017.11.030] [PMID: 29117536]